.png){kind=icon}
Return
Osilodrostat: First Approval
.png){kind=icon}
PRE
AI
DOI：10.1007/s40265-020-01277-0.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Osilodrostat (Isturisa (R)) is an orally available small molecule 11 beta-hydroxylase inhibitor that is being developed by Novartis for the treatment of Cushing's disease. Based on results from a pivotal phase III trial, osilodrostat was approved in the EU for use in the treatment of endogenous Cushing's syndrome in adults and is under regulatory review in the USA for the treatment of Cushing's disease. This article summarises the milestones in the development of osilodrostat leading to this first approval.
Keywords:
11-BETA-HYDROXYLASE INHIBITOR
LCI699
Journal
IF:
14.4
Papers:
8.4K
Citations:
2.3W
Organization
No organization information available
Cited Papers
Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.png)
PITUITARY
OAAI
PITUITARYIF3.4
OAAIShareSaveShareSave no more
no more